Stockscreener 앱 받기
6.00
9.77%
-0.65
시간 외 거래:
5.99
-0.010
-0.17%
Lexeo Therapeutics Inc 주식(LXEO)의 최신 뉴스
(LXEO) Trading Advice - Stock Traders Daily
Chardan Capital Brokers Decrease Earnings Estimates for LXEO - MarketBeat
Equities Analysts Set Expectations for LXEO FY2024 Earnings - MarketBeat
Lexeo Therapeutics (NASDAQ:LXEO) Stock Price Expected to Rise, HC Wainwright Analyst Says - Defense World
What is HC Wainwright's Forecast for LXEO FY2024 Earnings? - MarketBeat
Lexeo Therapeutics (NASDAQ:LXEO) Stock Price Expected to Rise, Chardan Capital Analyst Says - Defense World
Lexeo Therapeutics Advances Cardiac Portfolio Amid Financial Report - TipRanks
Janus Henderson Group PLC's Strategic Acquisition in Lexeo Thera - GuruFocus.com
Eventide Asset Management's Strategic Reduction in Lexeo Therape - GuruFocus.com
Lexeo Therapeutics Strengthens Leadership with New Board Appointment - TipRanks
Lexeo Therapeutics Provides Update on Cardiac Portfolio and Reports Third Quarter 2024 Financial Results - The Manila Times
Lexeo Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Lexeo Therapeutics Secures FDA Alignment, Reports $157M Cash Position Despite Q3 Loss | LXEO Stock News - StockTitan
Lexeo stock hits 52-week low at $7.54 amid market challenges By Investing.com - Investing.com South Africa
Lexeo stock hits 52-week low at $7.54 amid market challenges - Investing.com India
When (LXEO) Moves Investors should Listen - Stock Traders Daily
Analysts Set Lexeo Therapeutics, Inc. (NASDAQ:LXEO) PT at $22.14 - MarketBeat
Lexeo Therapeutics (NASDAQ:LXEO) Earns Buy Rating from HC Wainwright - MarketBeat
Lexeo shares dip on early data with Alzheimer's gene therapy - pharmaphorum
Lexeo reports positive Alzheimer's drug trial results - Investing.com India
Lexeo reports positive Alzheimer's drug trial results By Investing.com - Investing.com South Africa
Lexeo Therapeutics Announces Positive Interim Data for - GlobeNewswire
How now, tau? ‘Newer science’ shines in Lexeo Alzheimer’s data - BioWorld Online
Lexeo Therapeutics Sees Positive Results for Alzheimer's Disease Treatment - MarketWatch
Lexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to - The Bakersfield Californian
Lexeo Therapeutics Announces Positive Interim Data for LX1001, First-Ever Gene Therapy to Impact the Underlying Genetic Cause of APOE4-Associated Alzheimer’s Disease, at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference - StockTitan
Lexeo Therapeutics’ (LXEO) “Buy” Rating Reiterated at Chardan Capital - Defense World
(LXEO) Investment Analysis - Stock Traders Daily
Novo Holdings A S Trims Position in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - MarketBeat
Lexeo Therapeutics' (LXEO) "Buy" Rating Reaffirmed at Chardan Capital - MarketBeat
Lexeo Therapeutics to Present New Interim Data from Phase 1/2 Trial of LX1001 at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Conference - The Manila Times
Lexeo Therapeutics to Present New Interim Data from Phase - GlobeNewswire
Lexeo Therapeutics to Present New Interim Data from Phase 1/2 Trial of LX1001 at the Clinical Trials on Alzheimer’s Disease (CTAD) 2024 Conference - StockTitan
R. Nolan Townsend - Crain's New York Business
(LXEO) Proactive Strategies - Stock Traders Daily
Insider Selling: Lexeo Therapeutics, Inc. (NASDAQ:LXEO) CEO Sells 5,000 Shares of Stock - MarketBeat
Lexeon therapeutics CEO sells $40,495 in shares - Investing.com
Lexeo Therapeutics (NASDAQ:LXEO) Files 8-K Disclosing Change in Directors or Principal Officers - MarketBeat
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives Average Recommendation of "Buy" from Analysts - MarketBeat
Long Term Trading Analysis for (LXEO) - Stock Traders Daily
Lexeo Therapeutics' SWOT analysis: gene therapy stock poised for growth - Investing.com India
Novo Holdings A S Reduces Stock Position in Lexeo Therapeutics, Inc. (NASDAQ:LXEO) - MarketBeat
Lexeo Therapeutics' SWOT analysis: gene therapy stock poised for growth By Investing.com - Investing.com UK
Can you now get a good deal on Lexicon Pharmaceuticals Inc’s shares? - US Post News
Aurobindo to acquire 49% stake in GLS Pharma for Rs 22.5 crore - The Economic Times
LXP Industrial Trust (NYSE:LXP) PT Raised to $11.00 at Evercore ISI - Defense World
Lexicon Pharmaceuticals President and COO Jeffrey Wade to step down - The Business Journals
How Analyst Ratings Affect Leap Therapeutics Inc Inc. (LPTX) Price Performance - The InvestChronicle
Quest Partners LLC Acquires 11,597 Shares of LXP Industrial Trust (NYSE:LXP) - Defense World
Financial Analysis: Lexaria Bioscience (NASDAQ:LEXX) & Xeris Biopharma (NASDAQ:XERS) - Defense World
Get in on Lexicon Pharmaceuticals Inc’s (LXRX) buy-in window today! - SETE News
LXP Industrial Trust price target raised to $11 from $10 at Evercore ISI - TipRanks
Investor’s Delight: Lexicon Pharmaceuticals Inc (LXRX) Closes Strong at 1.70, Up 1.80 - The Dwinnex
Objective long/short (LXEO) Report - Stock Traders Daily
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives $22.14 Consensus Price Target from Analysts - MarketBeat
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Short Interest Update - MarketBeat
Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Given Average Recommendation of “Buy” by Analysts - Defense World
Gene Therapies For Cardiomyopathies Market Growth Anticipated - openPR
3.66%
1.11%
자본화:
|
볼륨(24시간):